The CASCINATION team is eager to embark on this springs biggest IR event - and finally, in our home country!
We are happy to take on the role as the (unofficial) host company.
As we have grown over the years - so does out booth space. Once again, we will have two CAS-One IR systems present to give plenty of rich, hands-on experiences to interested physicians. We did this at CIRSE Barcelona last year, after the previous ECIO and CIRSE we had to force people to wait to try out CAS-One IR for themselves.
This year will feature our biggest release since our Ablation Confirmation software, AblaSure.
We are bringing Automatic Fusion to CAS-One IR wuth AblaFuse. No longer will organ movement - for whatever reason - or tissue deformation disrupt your plan, your needle verification, or most importantly, your ablation confirmation. With nearly NO physician input, CAS-One IR will fuse images to ensure procedural accuracy is kept in all phases of the Quality Ablation workflow. There are many more features which bring more value to percutaneous tumor treatments - Come by to see it for yourself - you can even bring a dataset (pre and post contrast enhanced CT) if you want to test AblaFuse yourself.
See our full landing page dedicated to the release here
Last year there were 10+ abstracts presented featuring the use of CAS-One IR. This year there we are certain there will also be multiple - including some very complex cases! We will update this post as the y become available.
Every year we analyze the agenda and call out what we believe to be the most interesting topics - please see below for our guide to "can't miss" sessions focused on ablation. From IR on the front likes of the Ukraine war, to proving economic value, to of course the specifics of ablation in certain tumors or organs, there is a lot to hear and see at this years ECIO.
Monday April 27th
CF 211 – Pushing the boundaries in HCC management: new horizons in… 8:30-10 Auditorium 1
211.1 … percuntanoues ablation - M. Pech
211.6 …artificial intelligence – F. Gomez Munoz
CFF 221 - Mastering local treatment of metastatic colorectal cancer 10:30-12:00 – Auditorium 1
221.2 From OR to IR to hybrid – A. Fretland
221.3 Implementing best practice in liver ablation: planning, monitoring and confirmation – B. Odisio
221.4 IRE, cryo, Y90 and SBRT for CRLM: when heat is not the answer – A Kovacs
221.5 Colorectal liver mets: How big is too big? How many is too many? - R. Bale
CFF 222 – Defining success in renal IO: outcomes that drive practice 10:30-12:00 Auditorium 2
222.1 Ablation techniques: what the data reveal – O. Moschovaki-Zeiger
222.2 Percutaneous ablation of T1a: standard of care? – O. Graumann
CF 243 – Shaping the future of IR: leadership, collaboration, and training across borders 15:00-16:30 Auditorium 3
243.1 Doing more with less: how to deal with fixed budgets and rising demands – M. van den Bosch
243.7 Frontline IR: delivering care during the war in Ukraine – O. Korshak
CF 252 – Setting standards, building evidence and driving impact in IO 17:00-18:00 Auditorium 2
252.1 Defining evidence standards in IO: choosing the right weapon for the right fight – H. Verkooijen
252.2 Beyond the numbers: defining “enough” in IO evidence generation – T. Gade
252.3 From data to decision-making: writing for policy and economic impact – M. Burgmans
252.4 Value over volume: when do we need health economic assessments? – M. Lamotte
Tuesday April 28th
CF 312 – Spinal metastases: multidisciplinary management – 8:30-10:00 Auditorium 2
312.3 Why ablation may be advantageous compared to radiation therapy? R. Cazzato
312.4 Can ablation provide more than "simple" pain relief? J. Jennings
SP 313 – Thermal and non-thermal liver tumour ablation – 8:30-10:00 Auditorium 3
313.1 A1 ablative margins in colorectal liver metastases: defining when to re-ablate using volume of insufficient coverage – an international multicenter study – I. Paolucci
313.2 Thermal ablation versus surgical resection for intermediate-size (3-5 cm) colorectal liver metastases: results from the Amsterdam Colorectal Liver Met Registry (AmCORE) – M. Dijkstra
313.3 Percutaneous microwave ablation of liver tumors: correspondence of the predicted ablation zone and the actual ablation zone – G. Van Erp
Wednesday April 29th
CF 412 – Management of extra-spinal bone metastases – 8:30-10:00 Auditorium 2
412.4 Expected results of ablation in palliative and curative scenarios – D. Filippiadis
CF 422 – What can the interventional radiologist do in the treatment of non-colorectal liver metastases? – 10:30-12:00 Auditorium 2
422.1 Neuroendocrine tumours – J. Ricke
422.2 Melanoma – M. Soulen
422.3 Breast – G. Narayanan
422.4 GIST and other primary gastrointestinal tumours – J. Erinjeri
422.5 Sarcoma – R. Iezzi
CF 423 – Cancer as a chronic disease – 10:30-12:00 Auditorium 3
423.1 Why I chose the minimally invasive option: a patient's perspective – C. van der Geest
423.2 Life with chronic cancer: a patient’s perspective – S. Patton
EM 442 – ECIO meets E-AHPBA: Cut or burn? When surgeons and interventional oncologists team up – 15:00-16:30 Auditorium 2
442.2 From collision to coalition: when ego meets evidence in the management of colorectal liver mets – A. Fretland
CFF 443 – Meet the PI – 15:00-16:30 Auditorium 3
443.1 The Dutch Model – M. Meijerink
443.2 CRYORL – R. Cazzato
443.4 COLLISION XL – P. van Rossum
443.7 Impact of ablation margin size on long-term outcomes after MWA of CRLM: results from the prospective CIEMAR registry – P. Pereira
443.8 The POLAR trial - A Phase I study of tumour cryOabLAtIon in combination with ipilimumab and nivolumab in front-line treatment of metastatic Renal cell carcinoma – J. Brandon
CF 452 – Smart tools, smarter IO - 17:00-18:30 Auditorium 2
452.1 Robotic and non-robotic tumour ablation and biopsy-guiding systems – R. Bale
452.2 AI-guided precision in tumour interventions from percutaneous to endovascular approaches – J. Martinez Rodrigo
452.3 Augmented reality for image-guided procedures in IO – M. van Strijen
452.5 IR suite of the future: Integrating AI, imaging, and data for real-time decision-making in IO – A. Najafi
Let the coundown continue! Looking forward to seeing you there.